| FORM 3 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
| |||||||||||||||
1. Name and Address of Reporting Person*
(Street)
| 2. Date of Event Requiring Statement (Month/Day/Year) 12/09/2016 | 3. Issuer Name and Ticker or Trading Symbol IMMUNOGEN INC [ IMGN ] | |||||||||||||
| 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
| 5. If Amendment, Date of Original Filed (Month/Day/Year) | ||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 6,000 | D | |
| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Stock Option (right to buy) | 04/01/2016(1) | 04/01/2025 | Common Stock | 125,000 | 8.94 | D | |
| Stock Option (right to buy) | 07/13/2016(2) | 07/13/2025 | Common Stock | 11,000 | 16.72 | D | |
| Stock Option (right to buy) | 06/01/2017(3) | 06/01/2026 | Common Stock | 4,000 | 5.75 | D | |
| Stock Option (right to buy) | 07/18/2017(4) | 07/18/2026 | Common Stock | 50,000 | 3.05 | D | |
| Stock Option (right to buy) | 09/30/2017(5) | 09/30/2026 | Common Stock | 50,000 | 2.68 | D | |
| Explanation of Responses: |
| 1. 31,250 shares exercisable as of filing date, 31,250 shares exercisable commencing on April 1, 2017, 31,250 shares exercisable commencing on April 1, 2018 and 31,250 shares exercisable commencing on April 1, 2019. |
| 2. 3,667 shares exercisable as of filing date, 3,667 shares exercisable commencing on July 13, 2017, and 3,666 shares exercisable commencing on July 13, 2018. |
| 3. Exercisable as to 1,334 shares commencing on June 1, 2017, 1,333 shares commencing on June 1, 2018, and 1,333 shares commencing on June 1, 2019. |
| 4. Exercisable as to 16,667 shares commencing on July 18, 2017, 16,667 shares commencing on July 18, 2018, and 16,666 shares commencing on July 18, 2019. |
| 5. Exercisable as to 16,667 shares commencing on September 30, 2017, 16,667 shares commencing on September 30, 2018, and 16,666 shares commencing on September 30, 2019. |
| /s/ Craig Barrows, attorney in fact | 12/16/2016 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
